Patents Represented by Attorney Lucy J. Incyte Pharmaceuticals, Inc. Billings
-
Patent number: 6130325Abstract: The present invention provides two human p24 vesicle trafficking proteins (designated individually as Hp24-1 and Hp24-2 and collectively as Hp24) and polynucleotides which identify and encode Hp24. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding Hp24 and a method for producing Hp24. The invention also provides for agonists, antibodies, or antagonists specifically binding Hp24, and their use, in the prevention and treatment of diseases associated with expression of Hp24. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding Hp24 for the treatment of diseases associated with the expression of Hp24. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding Hp24.Type: GrantFiled: February 14, 1997Date of Patent: October 10, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Olga Bandman
-
Patent number: 6080558Abstract: The invention provides a new human growth regulator protein (GRREG) and polynucleotides which identify and encode GRREG. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRREG.Type: GrantFiled: July 11, 1997Date of Patent: June 27, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Preeti Lal, Purvi Shah, Neil C. Corley
-
Patent number: 6060297Abstract: The present invention provides a human Rho protein (HRHO) and polynucleotides which identify and encode HRHO. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing HRHO and for treating or preventing disorders associated with expression of HRHO.Type: GrantFiled: April 17, 1997Date of Patent: May 9, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 6037164Abstract: The present invention provides a human parvulin-like protein (HPVLP) and polynucleotides which identify and encode HPVLP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPVLP and a method for producing HPVLP. The invention also provides for agonists, antibodies, or antagonists specifically binding HPVLP, and their use, in the prevention and treatment of diseases associated with expression of HPVLP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HPVLP for the treatment of diseases associated with the expression of HPVLP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HPVLP.Type: GrantFiled: February 14, 1997Date of Patent: March 14, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventor: Janice Au-Young
-
Patent number: 6033869Abstract: The present invention provides a human cytokine/steroid receptor protein (CYSTAR) and polynucleotides which identify and encode CYSTAR. The invention also provides expression vectors, host cells, antibodies and antagonists. The invention also provides methods for the prevention and treatment of diseases associated with expression of CYSTAR, as well as diagnostic assays.Type: GrantFiled: March 20, 1997Date of Patent: March 7, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventors: Surya K. Goli, Jennifer L. Hillman, Lynn E. Murry
-
Patent number: 6020179Abstract: The present invention provides novel human protein tyrosine phosphatases (HPTP) and polynucleotides which identify and encode HPTP. The invention provides for genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HPTP and for a method of producing HPTP. The invention also provides for pharmaceutical compositions comprising HPTP or antagonists of HPTP, and antibodies which specifically bind HPTP. Additionally, the invention provides antisense molecules to HPTP for treatment or prevention of diseases associated with abnormal expression of HPTP.Type: GrantFiled: October 3, 1996Date of Patent: February 1, 2000Assignee: Incyte Pharmaceuticals, Inc.Inventor: Surya K. Goli
-
Patent number: 5985606Abstract: The invention provides a human preprotachykinin B (PPT-B) and polynucleotides which identify and encode PPT-B. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PPT-B.Type: GrantFiled: June 19, 1997Date of Patent: November 16, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Matthew R. Kaser
-
Patent number: 5973130Abstract: The present invention provides a human Ras-like protein (RLP) and polynucleotides which identify and encode RLP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. In addition, the invention provides methods for producing RLP and for treating or preventing disorders associated with expression of RLP.Type: GrantFiled: April 30, 1997Date of Patent: October 26, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli, Neil C. Corley
-
Patent number: 5968798Abstract: The invention provides a human glutaredoxin .beta. (GRX.beta.) and polynucleotides which identify and encode GRX.beta.. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of GRX.beta..Type: GrantFiled: August 14, 1997Date of Patent: October 19, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah
-
Patent number: 5965395Abstract: The invention provides a human maternally transcribed protein (HMTP) and polynucleotides which identify and encode HMTP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HMTP.Type: GrantFiled: October 3, 1997Date of Patent: October 12, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley
-
Patent number: 5962300Abstract: The present invention provides a human tumor suppressor (HKALL) and polynucleotides which identify and encode HKALL. The invention also provides expression vectors and host cells, agonists, antibodies, or antagonists. The invention provides methods for treating diseases associated with expression of HKALL.Type: GrantFiled: March 26, 1997Date of Patent: October 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal
-
Patent number: 5962231Abstract: The invention provides a human glutathione-S-transferase (HGST) and polynucleotides which identify and encode HGST. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of HGST.Type: GrantFiled: September 30, 1997Date of Patent: October 5, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Henry Yue, Neil C. Corley, Purvi Shah
-
Patent number: 5955299Abstract: The present invention provides novel human small nuclear ribonucleoprotein (snRNP) Sm proteins (collectively called HSMP) and polynucleotides which identify and encode HSMP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HSMP. The invention also provides pharmaceutical compositions containing HSMP or antagonists to HSMP, and in the use of these compositions for the treatment of diseases associated with the expression of HSMP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HSMP for the treatment of diseases associated with the expression of HSMP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, to hybridize to the genomic sequence or transcripts of polynucleotides encoding HSMP or anti-HSMP antibodies which specifically bind to HSMP.Type: GrantFiled: September 27, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Olga Bandman, Gary B. Zweiger
-
Patent number: 5955302Abstract: The present invention provides a human dosage compensation-associated protein (HDCAP) and polynucleotides which encode HDCAP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HDCAP and a method for producing HDCAP. The invention also provides for agonists, antibodies, or antagonists specifically binding HDCAP, and their use, in the prevention and treatment of diseases associated with expression of HDCAP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HDCAP for the treatment of diseases associated with the expression of HDCAP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HDCAP.Type: GrantFiled: February 6, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Preeti Lal, Surya K. Goli
-
Patent number: 5955338Abstract: The invention provides a human phosphatidylinositol 4,5-bisphosphate 5-phosphatase (PBPP) and polynucleotides which identify and encode PBPP. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of PBPP.Type: GrantFiled: June 27, 1997Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Preeti Lal, Neil C. Corley, Purvi Shah
-
Patent number: 5955301Abstract: The present invention provides a human glutamate-binding protein (HGLUBP) and polynucleotides which identify and encode HGLUBP. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HGLUBP and a method for producing HGLUBP. The invention also provides for use of HGLUBP and agonists, antibodies, or antagonists specifically binding HGLUBP, in the prevention and treatment of diseases associated with expression of HGLUBP. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HGLUBP for the treatment of diseases associated with the expression of HGLUBP. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HGLUBP.Type: GrantFiled: November 14, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Roger Coleman
-
Patent number: 5955314Abstract: The present invention provides a human regulator of G-protein signaling (HRGS) and polynucleotides which identify and encode HRGS. The invention also provides genetically engineered expression vectors and host cells comprising the nucleic acid sequences encoding HRGS and a method for producing HRGS. The invention also provides for agonists, antibodies, or antagonists specifically binding HRGS, and their use, in the prevention and treatment of diseases associated with expression of HRGS. Additionally, the invention provides for the use of antisense molecules to polynucleotides encoding HRGS for the treatment of diseases associated with the expression of HRGS. The invention also provides diagnostic assays which utilize the polynucleotide, or fragments or the complement thereof, and antibodies specifically binding HRGS.Type: GrantFiled: November 8, 1996Date of Patent: September 21, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Surya K. Goli
-
Patent number: 5945306Abstract: The invention provides two human Ras proteins, referred to collectively as "RAPR" and individually as "RAPR-1" and "RAPR-2", and polynucleotides which identify and encode RAPR. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for preventing and treating disorders associated with expression of RAPR.Type: GrantFiled: December 16, 1997Date of Patent: August 31, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Olga Bandman, Jennifer L. Hillman, Karl J. Guegler, Y. Tom Tang, Neil C. Corley
-
Patent number: 5945330Abstract: The invention provides two human longevity-assurance protein homologs, designated individually as LAPH-1 and LAPH-2 and collectively as LAPH, and polynucleotides which identify and encode LAPH. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of LAPH.Type: GrantFiled: July 30, 1997Date of Patent: August 31, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Jennifer L. Hillman, Neil C. Corley, Purvi Shah, Preeti Lal
-
Patent number: 5936068Abstract: The present invention provides nucleotide and amino acid sequences that identify and encode novel expressed chemokines (ECs) from liver and pituitary gland tissues. The present invention also provides for antisense molecules to the nucleotide sequences which encode ECs, expression vectors for the production of purified ECs, antibodies capable of binding specifically to ECs, hybridization probes or oligonucleotides for the detection of EC-encoding nucleotide sequences, genetically engineered host cells for the expression of ECs, diagnostic tests for inflammation or disease based on on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs, pharmaceutical compositions to treat inflammation or disease based on EC-encoding nucleic acid molecules or antibodies capable of binding specifically to ECs.Type: GrantFiled: February 10, 1997Date of Patent: August 10, 1999Assignee: Incyte Pharmaceuticals, Inc.Inventors: Craig G. Wilde, Phillip R. Hawkins, Olga Bandman, Jeffrey J. Seilhamer